论文部分内容阅读
目的:观察静脉注射不同剂量HPPH光敏剂后不同时段透过血脑屏障在颅内外肿瘤与正常脑组织、皮肤间的代谢分布,并确定静脉注射HPPH光敏剂后在脑胶质瘤高浓度聚集与正常组织大部份排出相差距离最大的时间段,为光敏诊断、光动力治疗提供最佳时间及剂量。方法:建立鼠G422脑胶质瘤、腋部皮下移植瘤模型,设立注射HPPH 0.15mg/kg组、HPPH 0.3mg/kg组、HPPH 0.45mg/kg组、以荧光图像早期癌诊断仪测定注药前、注药后(4、8、12、18、24、32、48h)肿瘤及正常脑组织、皮肤、口腔及眼粘膜的荧光峰值,选择在肿瘤中有较高的HPPH浓度,正常脑组织及皮肤大部分已排出的最大距离值,以确定HPPHPDT,HPPH注药后最佳的诊断、治疗时间及剂量。结果:从鼠G422脑胶质瘤、腋部皮下移植瘤模型注HPPH 0.15mg/kg组、HPPH 0.3mg/kg组、HPPH 0.45mg/kg组、以荧光图像早期癌诊断仪测定注药前、注药后(4、8、12、18、24、32、48h)不同时间脑肿瘤、腋部皮下肿瘤、正常脑、正常皮肤、口腔及眼粘膜的荧光峰值看,HPPH在注药后12～24h时正常组织荧光峰已较低,而肿瘤尚有较高的荧光峰,二者的距离也较大,是作荧光诊断及光动力学治疗的较佳时间,HPPH 0.3mg/kg、HPPH 0.45mg/kg组峰值平均值接近,并稍高于HPPH 0.15mg/kg组,故HPPH注药0.3mg/kg、注药后12～24h是作鼠G422脑胶质瘤肿瘤光敏诊断及光动力学治疗的较佳剂量及时间,三组注药后口腔及眼粘膜的荧光峰值均较高,且48h仍有较高的浓度,应注意口、眼在HPPH-PDT后对光的防护。皮肤48h时荧光峰较低,可减少皮肤避光时间。结论:通过荧光图像早期癌诊断仪测定静脉注射HPPH在肿瘤及正常组织中的代谢,确定HPPH能作光敏诊断及光动力学治疗,注药0.3mg/kg、注药后12～24h是较佳的光敏诊断及光动力学治疗的剂量及时间。
OBJECTIVE: To observe the metabolic distribution of intracerebral and extracranial tumors and normal brain tissue and skin at different time intervals after intravenous injection of different doses of HPPH photosensitizer, and to determine whether HPPH photosensitizer intravenously injected at high concentration in glioma Most of the normal tissue discharge the most time-consuming distance for the photosensitive diagnosis, photodynamic therapy to provide the best time and dose. Methods: The mouse model of G422 glioma and axillary subcutaneous xenografts was established. Injection of HPPH 0.15 mg / kg, HPPH 0.3 mg / kg, and HPPH 0.45 mg / kg were established. Fluorescent images of early cancer diagnosis instrument Before injection (4,8,12,18,24,32,48h) after injection of tumor and normal brain tissue, skin, oral and ocular mucosa peak fluorescence, the choice of higher HPPH concentration in the tumor, normal brain tissue And most of the skin has been discharged the maximum distance value to determine the HPPHPDT, HPPH injection after the best diagnosis, treatment time and dose. Results: From the G422 glioma and axillary subcutaneous xenograft models, HPPH 0.15 mg / kg group, HPPH 0.3 mg / kg group and HPPH 0.45 mg / kg group were injected with fluorescence imaging early cancer diagnostic instrument before injection, At 4, 12, 12, 18, 24, 32, and 48h after injection, the fluorescence peaks of brain tumor, subcutaneous axillary tumors, normal brain, normal skin, oral cavity and ocular mucosa were observed at different time points. Fluorescence peak of normal tissue at 24 hours was lower, while the tumor had higher fluorescence peak, and the distance between the two was larger, which was the best time for fluorescence diagnosis and photodynamic therapy. HPPH 0.3 mg / kg and HPPH 0.45 mg / kg group peak average close to, and slightly higher than the HPPH 0.15mg / kg group, so HPPH injection 0.3mg / kg, 12 ~ 24h after injection is a mouse G422 brain glioma tumor photodynamic diagnosis and photodynamic The best dose and time of treatment, the fluorescence peaks of oral and ocular mucosa were all higher after three groups of injection, and the concentration was still high after 48h. It should pay attention to the protection of eyes and eyes after light-up of HPPH-PDT. Fluorescence peak 48h lower skin can reduce the skin dark time. CONCLUSIONS: HPPH can be used as a photosensitizer and photodynamic therapy to determine the metabolism of HPPH in tumors and normal tissues by fluorescence imaging of early cancer diagnostic apparatus. Injection of 0.3mg / kg, 12 ~ 24h after injection is better Of the photosensitive diagnosis and photodynamic therapy dose and time.